Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 17Ovarian Neoplasms 11Neoplasms 8Fallopian Tube Neoplasms 8Triple Negative Breast Neoplasms 7Prostatic Neoplasms 6Neoplasm Metastasis 6Pancreatic Neoplasms 4Endometrial Neoplasms 4Neuroendocrine Tumors 3Glioma 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Recurrence 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Fanconi Anemia, Complementation Group D1 2Cholangiocarcinoma 2Uveal Melanoma 1Urogenital Neoplasms 1Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1SCLC,Extensive Stage 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Platinum-sensitive Ovarian Cancer 1

Interventions

olaparib 1decitabine and cedazuridine drug combination 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × BRCA1 Mutation × olaparib × Clear all
NCT06177171 2026-05-27

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

University of California, San Francisco

Phase 1 Recruiting
18 enrolled

BRCA1 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡